Literature DB >> 28645621

Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.

Elyssa B Margolis1, Wakako Fujita2, Lakshmi A Devi2, Howard L Fields3.   

Abstract

The mu and delta opioid receptors (MOR and DOR) are highly homologous members of the opioid family of GPCRs. There is evidence that MOR and DOR interact, however the extent to which these interactions occur in vivo and affect synaptic function is unknown. There are two stable DOR subtypes: DPDPE sensitive (DOR1) and deltorphin II sensitive (DOR2); both agonists are blocked by DOR selective antagonists. Robust motivational effects are produced by local actions of both MOR and DOR ligands in the ventral tegmental area (VTA). Here we demonstrate that a majority of both dopaminergic and non-dopaminergic VTA neurons express combinations of functional DOR1, DOR2, and/or MOR, and that within a single VTA neuron, DOR1, DOR2, and MOR agonists can differentially couple to downstream signaling pathways. As reported for the MOR agonist DAMGO, DPDPE and deltorphin II produced either a predominant K+ dependent hyperpolarization or a Cav2.1 mediated depolarization in different neurons. In some neurons DPDPE and deltorphin II produced opposite responses. Excitation, inhibition, or no effect by DAMGO did not predict the response to DPDPE or deltorphin II, arguing against a MOR-DOR interaction generating DOR subtypes. However, in a subset of VTA neurons the DOR antagonist TIPP-Ψ augmented DAMGO responses; we also observed DPDPE or deltorphin II responses augmented by the MOR selective antagonist CTAP. These findings directly support the existence of two independent, stable forms of the DOR, and show that MOR and DOR can interact in some neurons to alter downstream signaling.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ca(v)2.1; D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH(2) (CTAP) (PubChem CID: 10418702); Delta opioid receptor; H-Tyr-Tic-psi(CH(2)NH)Phe-Phe-OH (TIPP-psi) (PubChem CID: 5311481); Ventral tegmental area; [D-Ala(2), Glu(4)]deltorphin (deltorphin II) (PubChem CID: 123795); [D-Ala(2), N-Me-Phe(4), Gly-ol(5)]-Enkephalin acetate salt (DAMGO) (PubChem CID: 5462471); [D-Pen(2), D-Pen(5)]enkephalin (DPDPE) (PubChem CID:104787); mu opioid receptor

Mesh:

Substances:

Year:  2017        PMID: 28645621      PMCID: PMC5563499          DOI: 10.1016/j.neuropharm.2017.06.019

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  81 in total

1.  GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area.

Authors:  P W Kalivas; L Churchill; M A Klitenick
Journal:  Neuroscience       Date:  1993-12       Impact factor: 3.590

2.  Direct bidirectional μ-opioid control of midbrain dopamine neurons.

Authors:  Elyssa B Margolis; Gregory O Hjelmstad; Wakako Fujita; Howard L Fields
Journal:  J Neurosci       Date:  2014-10-29       Impact factor: 6.167

3.  CRF-R2 and the heterosynaptic regulation of VTA glutamate during reinstatement of cocaine seeking.

Authors:  Courtney L Williams; William C Buchta; Arthur C Riegel
Journal:  J Neurosci       Date:  2014-07-30       Impact factor: 6.167

4.  Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats.

Authors:  M A Bozarth
Journal:  Brain Res       Date:  1987-06-23       Impact factor: 3.252

5.  Two types of neurone in the rat ventral tegmental area and their synaptic inputs.

Authors:  S W Johnson; R A North
Journal:  J Physiol       Date:  1992-05       Impact factor: 5.182

6.  Intra-VTA deltorphin, but not DPDPE, induces place preference in ethanol-drinking rats: distinct DOR-1 and DOR-2 mechanisms control ethanol consumption and reward.

Authors:  Jennifer M Mitchell; Elyssa B Margolis; Allison R Coker; Daicia C Allen; Howard L Fields
Journal:  Alcohol Clin Exp Res       Date:  2013-08-27       Impact factor: 3.455

7.  Ventral mesencephalic delta opioid receptors are involved in modulation of basal mesolimbic dopamine neurotransmission: an anatomical localization study.

Authors:  D P Devine; P Leone; W A Carlezon; R A Wise
Journal:  Brain Res       Date:  1993-09-17       Impact factor: 3.252

8.  Ventral tegmental area opioid mechanisms and modulation of ingestive behavior.

Authors:  A Badiani; P Leone; M B Noel; J Stewart
Journal:  Brain Res       Date:  1995-01-30       Impact factor: 3.252

9.  Preferred supramolecular organization and dimer interfaces of opioid receptors from simulated self-association.

Authors:  Davide Provasi; Mustafa Burak Boz; Jennifer M Johnston; Marta Filizola
Journal:  PLoS Comput Biol       Date:  2015-03-30       Impact factor: 4.475

10.  Structural Mechanisms of Voltage Sensing in G Protein-Coupled Receptors.

Authors:  Owen N Vickery; Jan-Philipp Machtens; Giulia Tamburrino; Daniel Seeliger; Ulrich Zachariae
Journal:  Structure       Date:  2016-05-19       Impact factor: 5.006

View more
  12 in total

Review 1.  Endogenous Opioids at the Intersection of Opioid Addiction, Pain, and Depression: The Search for a Precision Medicine Approach.

Authors:  Michael A Emery; Huda Akil
Journal:  Annu Rev Neurosci       Date:  2020-02-28       Impact factor: 12.449

2.  Delta/mu opioid receptor interactions in operant conditioning assays of pain-depressed responding and drug-induced rate suppression: assessment of therapeutic index in male Sprague Dawley rats.

Authors:  Katherine Cone; Janell Lanpher; Abigail Kinens; Philomena Richard; Sarah Couture; Rebecca Brackin; Emily Payne; Kylee Harrington; Kenner C Rice; Glenn W Stevenson
Journal:  Psychopharmacology (Berl)       Date:  2018-03-23       Impact factor: 4.530

3.  Opioid-Induced Signaling and Antinociception Are Modulated by the Recently Deorphanized Receptor, GPR171.

Authors:  Max V McDermott; Leela Afrose; Ivone Gomes; Lakshmi A Devi; Erin N Bobeck
Journal:  J Pharmacol Exp Ther       Date:  2019-07-15       Impact factor: 4.030

Review 4.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

5.  Convergent, functionally independent signaling by mu and delta opioid receptors in hippocampal parvalbumin interneurons.

Authors:  Xinyi Jenny He; Janki Patel; Connor E Weiss; Xiang Ma; Brenda L Bloodgood; Matthew R Banghart
Journal:  Elife       Date:  2021-11-17       Impact factor: 8.140

Review 6.  Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain.

Authors:  Kaitlin C Reeves; Nikhil Shah; Braulio Muñoz; Brady K Atwood
Journal:  Front Mol Neurosci       Date:  2022-06-15       Impact factor: 6.261

7.  Characterization of a Multiple-Scan-Rate Voltammetric Waveform for Real-Time Detection of Met-Enkephalin.

Authors:  S E Calhoun; C J Meunier; C A Lee; G S McCarty; L A Sombers
Journal:  ACS Chem Neurosci       Date:  2019-01-12       Impact factor: 4.418

Review 8.  Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo.

Authors:  Muzeyyen Ugur; Lyes Derouiche; Dominique Massotte
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

9.  Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon.

Authors:  Jesse J DiCello; Simona E Carbone; Ayame Saito; Pradeep Rajasekhar; Rhian A Ceredig; Vi Pham; Celine Valant; Arthur Christopoulos; Nicholas A Veldhuis; Meritxell Canals; Dominique Massotte; Daniel P Poole
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-11-20

10.  Mechanical stimulation of cervical vertebrae modulates the discharge activity of ventral tegmental area neurons and dopamine release in the nucleus accumbens.

Authors:  Kyle B Bills; J Daniel Obray; Travis Clarke; Mandy Parsons; James Brundage; Chae Ha Yang; Hee Young Kim; Jordan T Yorgason; Jonathan D Blotter; Scott C Steffensen
Journal:  Brain Stimul       Date:  2019-12-04       Impact factor: 8.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.